EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives

Vikrant Rai iD

Biomolecules · 22.05.2025 · 15 (6) · 751

DOI: 10.3390/biom15060751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 22.05.2025. Verfasst von Vikrant Rai. Beteiligte Einrichtung: Department of Translational Research, Western University of Health Sciences, Pomona, CA 91762, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Prostatic Neoplasms, Immunotherapy, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer, a slow-growing tumor, develops through the over-proliferation of malignant cells in the prostate and is one of the most common types of cancer. Active surveillance, radical prostatectomy, external beam radiation, brachytherapy, cryotherapy, stereotactic body radiation therapy, hormone therapy, and chemotherapy are common treatment strategies for prostate cancer. However, resistance to treatment in advanced prostate cancer is a concerning issue in the use of these therapies. Immune checkpoint inhibitor (ICI) therapy for prostate cancer is an emerging strategy for the treatment of advanced prostate cancers but the resistance and limited efficacy to ICIs observed in metastatic castration-resistant prostate cancer (mCRPC) raises concerns. The ongoing clinical trials for combination therapies for mCRPC have provided some hope. This review concisely discusses the molecular and cellular mechanisms, immunotherapy, the limitations of ICIs, combination therapies, and the prospects of developing novel therapeutics for prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsProstatic NeoplasmsImmunotherapyProstatic Neoplasms, Castration-ResistantHumansMaleCombined Modality Therapy

Stichwörter der Autor:innen

combination therapiesimmunotherapylimitation to immunotherapymolecular mechanismsprostate cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Translational Research, Western University of Health Sciences, Pomona, CA 91762, USA.

ORCID-Profile: Vikrant Rai

Zitieren

APA

Rai, V. (2025). Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives. Biomolecules, 15(6), 751. https://doi.org/10.3390/biom15060751

Vancouver

Rai V. Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives. Biomolecules. 2025;15(6):751. doi:10.3390/biom15060751

BibTeX
@article{Rai2025,
  author = {Rai, Vikrant},
  title = {Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {751},
  doi = {10.3390/biom15060751}
}
Kostenlos starten →